r treatment and cancer clinical trials," said Peach, "in which patients are quickly moved into appropriate trials based on their individual genetics. And, because almost all drug trials are delayed due to lags in enrollment, UK research will benefit from this model as well."
The 150 genes in the Oxford study will be selected with input from pharmaceutical companies, as genes of interest for potential new drug targets or markers for efficacy of existing drugs or those under development.
Fast and economical Personal Genome Machines will enable affordable price point for nine gene report
The consortium will create and validate the new NGS-based test on the Ion Torrent™ Personal Genome Machine™ (PGM), a next generation sequencing platform that can sequence hundreds of genes in just two hours. The semi-conductor based PGM was selected for its ease of use, speed, accuracy, and economic pricing. The new test will include a report on nine known genetic markers at a price that is affordable within the National Health Service.
"Rapid, cost-effective sequencing is taking us into a new genomic knowledge economy," said Paul Billings, M.D., Ph.D., chief medical officer of Life Technologies. "We are approaching an entirely new way to address, diagnose and treat cancer. In the near future, we see DNA sequencing as a routine part of patient care, generating a new kind of valuable information as a decision resource to physicians."
Life Technologies has a strong presence in the U.K., with over 700 employees in research & development, manufacturing, and commercial operations; its European headquarters is in Paisley, Scotland.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company dedicated to improving the human condition. Our systems, con
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Life Technologies Corporation|
Copyright©2010 PR Newswire.
All rights reserved
. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results2
. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction3
. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study4
. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study5
. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures6
. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure7
. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results8
. Senesco Technologies Initiates Preclinical Studies for Cancer Target9
. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer10
. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine11
. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY